Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of 1-diphenylmethyl-4-methylpiperazine compound in preparation of anti-depression drug

A benzhydryl compound technology, applied in the field of medicine, can solve the problems of complex pathogenesis of depression and inconclusive mechanism

Active Publication Date: 2021-01-22
SOUTHEAST UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The pathogenesis of depression is complex, and it is generally believed that its pathogenesis is related to factors such as genetics, neuroendocrine, immunity, and psychosocial environment, but the exact mechanism is still inconclusive

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of 1-diphenylmethyl-4-methylpiperazine compound in preparation of anti-depression drug
  • Application of 1-diphenylmethyl-4-methylpiperazine compound in preparation of anti-depression drug
  • Application of 1-diphenylmethyl-4-methylpiperazine compound in preparation of anti-depression drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] The establishment of the mouse chronic unpredictable stress model of embodiment 1:

[0026] A mouse model of chronic unpredictable stress was established by exposing mice to various randomly scheduled low-intensity social and environmental stressors 1-2 times a day for 4 weeks.

[0027] Random stressors included: 1) restraint for 6 hours; 2) cage tilting at 45° along a vertical axis for 3 hours; 3) water and food deprivation (for 24 hours, then normal afterward); 4) circadian light reversal; 5) no pad 6) Tail clamping for 1 minute (1 cm from the base of the tail); 7) Wet litter for 24 hours; 8) Forced swimming at 8°C for 5 minutes.

[0028] Experimental group:

[0029] 1) Control group: control mice;

[0030] 2) Model group: the above-mentioned chronic unpredictable stress model was used for modeling;

[0031] 3) Positive reference group: Fluoxetine was used as the positive reference drug, administered by intraperitoneal injection, 10 mg / kg / day, for 4 weeks;

[0032...

Embodiment 2

[0033] Embodiment 2 sucrose preference test

[0034] The sucrose preference test was conducted in three phases: the first phase habituation, the second phase sucrose preference baseline, and the third phase sucrose preference test. Phase 1: Mice are acclimatized with sucrose at a concentration of 1%. The second stage: each mouse was reared in a single cage, and the mice were given the same amount of normal drinking water and 1% sucrose solution, and the positions of the normal drinking water and sucrose water bottles were changed every 6 hours. The consumption of normal drinking water and 1% sucrose solution was recorded for 24 hours, and the sucrose baseline of the animals was calculated. In the third stage, each mouse was reared in a single cage, and the mice were given the same amount of normal drinking water and 1% sucrose solution, and the positions of the normal drinking water and sucrose water bottles were changed every 6 hours. The consumption of normal drinking wate...

Embodiment 3

[0037] Embodiment 3 Tail Suspension Experiment Test

[0038] During the tail suspension test, the mice were suspended on the top of the equipment box 50 cm above the ground. The experiment time is 6 minutes, the first 2 minutes is the adaptation time of the mice, and the last 4 minutes is the test time. The immobility time of the mice within 4 min after recording was recorded.

[0039] Immobility time: the mouse is in a suspended state without any body movements. Immobility time was measured using the ANY maze tracking system (Stoelting Co, Wood Dale, Illinois).

[0040] Results: The immobility time of the mice in the model group increased significantly, and the compound 1-benzhydryl-4-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)piperazine It can significantly reduce the immobility time of mice and alleviate the depression-like symptoms of mice, and the effect is consistent with that of the positive reference drug fluoxetine.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of a 1-diphenylmethyl-4-methylpiperazine compound in preparation of an anti-depression drug, and belongs to the field of medicines. The compound 1-diphenylmethyl-4-((1-phenyl-1H-1, 2, 3-triazol-4-yl) methyl) piperazine can significantly improve the depression-like behavior of a chronic unpredictable stress model mouse. Mechanism studies suggest that the compound l-diphenylmethyl-4-((l-phenyl-lH-l, 2, 3-triazol-4-yl) methyl) piperazine can ameliorate mouse intestinal flora disorders induced by a chronic unpredictable stress model; and the compound has a protective effect on the integrity of intestinal barriers and blood-brain barriers.

Description

technical field [0001] The disclosure belongs to the technical field of medicine, and specifically relates to a compound 1-benzhydryl-4-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)piperazine in Application in the preparation of antidepressant drugs. Background technique [0002] Depression is a common mental illness, mainly manifested as low mood, loss of interest, pessimism, slow thinking, lack of initiative, self-blame, poor diet and sleep, etc. In severe cases, suicidal thoughts and behaviors may appear. Serious physical and mental harm. With social and economic development, the pace of life continues to accelerate, and the incidence of depression increases year by year. In 2019, the number of depressed patients worldwide exceeded 350 million. It is estimated that by 2030, depression will become the world's largest burden disease. The pathogenesis of depression is complex, and it is generally believed that its pathogenesis is related to factors such as genetics, neuroendocr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/496A61P25/24
CPCA61K31/496A61P25/24A61P1/00A23V2002/00A23L33/10A23V2200/32
Inventor 姚红红张媛沈灵唐天慈
Owner SOUTHEAST UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com